Results 61 to 70 of about 8,252,790 (324)

Drug approval processes: A case study of rivaroxaban

open access: yesArchives of Pharmacy Practice, 2013
Rivaroxaban, a Xa inhibitor, was recently approved (March 2013) in the setting of post-acute coronary syndromes (ACS) by the European Medicine Agency. This is in contrast to not being approved by the Food and Drug Agency in the United States for the same
Sally A Arif, Zainab Bilfaqi
doaj   +1 more source

Ten‐Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs

open access: yesJournal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2020
Background In 1993, the US Food and Drug Administration established guidelines to increase diversity by sex and race/ethnicity of participants in clinical trials supporting novel drug approvals.
M. Khan   +7 more
semanticscholar   +1 more source

Biphasic Clinical Course of Pediatric Cytomegalovirus‐Associated Immune Thrombocytopenia: Early Poor Treatment Response but Favorable Long‐Term Outcomes

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cytomegalovirus (CMV) is a recognized trigger of immune thrombocytopenia (ITP); however, its incidence and impact on disease course in children remain controversial. Therefore, we aimed to characterize the clinical course of pediatric patients with CMV‐associated ITP.
Oded Gilad   +9 more
wiley   +1 more source

Transition from drug lag to drug loss in pediatric oncology: a comprehensive evaluation of the Japan-U.S. approval gap

open access: yesFrontiers in Pharmacology
IntroductionPediatric drug development in Japan faces significant challenges caused by the case rarity and limited commercial incentives. Although the United States (U.S.) RACE Act in 2017 has accelerated pediatric oncology approvals in the U.S., it has ...
Kana Yamada   +2 more
doaj   +1 more source

Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU

open access: yesClinical and Translational Science, 2023
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) offer expedited regulatory approval programs for drugs with high potential patient value applicable at different stages leading to marketing authorization: (i) drug ...
Ebru Demirci   +2 more
doaj   +1 more source

A review of new drugs approved by the food and drug administration in 2022

open access: yesJournal of Family Medicine and Primary Care, 2023
Introduction: The drugs approved by the Food and Drug Administration (FDA) in 2022, for the first time for any indication or under any brand, were studied under the contexts of indications, mechanism of action, and side effects.
Arjun Swaminathan   +2 more
doaj   +1 more source

Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016

open access: yesJAMA Network Open, 2020
Key Points Question What are the available data on cancer treatment outcomes for new cancer therapies approved by the US Food and Drug Administration?
Aviv Ladanie   +15 more
semanticscholar   +1 more source

Bone Mineral Density After Contemporary Treatment for Acute Lymphoblastic Leukaemia: A Matched Cross‐Sectional Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Reduced bone mineral density (BMD) has been reported in survivors of childhood and young adult acute lymphoblastic leukaemia (ALL); however, data from cohorts treated with contemporary protocols and including matched controls remain limited.
Karen Schow Jensen   +10 more
wiley   +1 more source

Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries

open access: yesRevista Panamericana de Salud Pública, 2021
Objective. To describe the current status of regulatory reliance in Latin America and the Caribbean (LAC) by assessing the countries’ regulatory frameworks to approve new medicines, and to ascertain, for each country, which foreign regulators are ...
Carlos E. Durán   +6 more
doaj   +1 more source

How to use FDA drug approval documents for evidence syntheses

open access: yesBritish medical journal, 2018
Evidence syntheses may benefit from using aggregated clinical trial information in approval documents published online by the US Food and Drug Administration (FDA).
Aviv Ladanie   +3 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy